Drug Trial Radar · NCT07426484
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
Dec 15, 2030
Study completion Dec 15, 2032
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Checkpoint Therapeutics, Inc.
- First posted
- Feb 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)
Conditions
- Cutaneous Squamous Cell Carcinoma
- Skin Cancer
Interventions
CosibelimabDrug
Anti-PD-L1 antibody, single dose vials, via intravenous (into the vein) infusion per protocol
PrednisoneDrug
Corticosteroid, per standard of care
SirolimusDrug
mTOR Inhibitor, per standard of care
EverolimusDrug
mTOR Inhibitor, per standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Overall Response Rate (BORR)Time frame: Up to 102 weeks.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.